Polyrizon Completes Enrollment of 120 Patients in U.S. Allergy-Blocker Study
Polyrizon said enrollment is complete for all 120 patients in its U.S. clinical study of Nasarix allergy blocker.
Polyrizon said enrollment is complete for all 120 patients in its U.S. clinical study of Nasarix allergy blocker.